Clinical Edge Journal Scan

Childbirth does not impact survival in women with previously treated BC


 

Key clinical point: A live birth (LB) after the diagnosis of breast cancer (BC) does not have a negative impact on a woman’s overall survival.

Major finding: Compared with women with no subsequent LB after BC diagnosis, the overall cohort of women with subsequent LB (hazard ratio [HR] 0.65; P = .002), women with only 1 subsequent LB (HR 0.73; P = .033), women with subsequent LB and no prior history of pregnancy (HR 0.56; P = .003), and women with LB within 5 years of BC diagnosis (HR 0.66; P = .006) had improved survival.

Study details: Findings are from a survival analysis in a national cohort of 5181 women diagnosed with BC at the age of 20-39 years, of which 290 had ≥1 LB and 1682 had no LB after BC diagnosis.

Disclosures: This study was partly supported by the MRC Centre for Reproductive Health, UK. Two authors declared serving as consultants or receiving speaker honoraria from several sources.

Source: Anderson RA et al. Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy. Eur J Cancer. 2022;173:113-122 (Jul 19). Doi: 10.1016/j.ejca.2022.06.048

Recommended Reading

The ‘great dynamism’ of radiation oncology
MDedge Hematology and Oncology
Lung adverse effects in patients taking trastuzumab deruxtecan
MDedge Hematology and Oncology
Pembrolizumab+chemotherapy improves OS in a subgroup of patients with advanced TNBC
MDedge Hematology and Oncology
Bed boost after WBI reduces local recurrence of ductal carcinoma in situ in the breast
MDedge Hematology and Oncology
TNBC: First-line nab-paclitaxel+cisplatin effective and safe in phase 3
MDedge Hematology and Oncology
ERBB2-positive BC: Adding atezolizumab to PATH shows acceptable pCR rate in phase 2
MDedge Hematology and Oncology
Oral paclitaxel+encequidar offers a possible alternative to IV paclitaxel in metastatic BC
MDedge Hematology and Oncology
ER+ HER2− early BC: Patients with PEPI 0-1/pCR can safely skip adjuvant chemotherapy
MDedge Hematology and Oncology
Early-stage ER+ BC: No recurrence or mortality with systemic or vaginal hormone therapy
MDedge Hematology and Oncology
ER+ BC: Long-term benefits of endocrine therapy in premenopausal women
MDedge Hematology and Oncology